Literature DB >> 30643413

Association between the SLC6A4 gene and schizophrenia: an updated meta-analysis.

Feng-Ling Xu1, Bao-Jie Wang1, Jun Yao1.   

Abstract

BACKGROUND: In order to explore the association between the SLC6A4 gene and the risk of schizophrenia, an updated meta-analysis was conducted using a total of 46 scientific articles.
METHODS: Through a literature search, papers studied included 35 articles on serotonin-transporter-linked polymorphic region (5-HTTLPR) with 8,752 cases and 10,610 controls, 17 articles on second intron variable number of tandem repeats with 7,284 cases and 8,544 controls, four studies on rs1042173 with 1,351 cases and 2,101 controls, and four studies on rs140700 with 1,770 cases and 2,386 controls. Pooled, subgroup, and sensitivity analyses were performed, and the results were visualized by forest and funnel plots.
RESULTS: An association between 5-HTTLPR and the risk of schizophrenia was not found, except for an Indian subgroup analysis (Pz =0.014, OR =1.749, 95% CI =1.120-2.731). A 10 repeats/12 repeats (10R/12R) genotype was a protective factor against schizophrenia (Pz =0.020, OR =0.789, 95% CI =0.646-0.963), but a 12R/12R genotype was a risk factor for schizophrenia (Pz =0.004, OR =1.936, 95% CI =1.238-3.029) in the pooled analyses. In Caucasians, a GG genotype of rs1042173 may be a risk factor for schizophrenia (Pz =0.006, OR =1.299, 95% CI =1.079-1.565). No association was found between rs140700 and the risk for schizophrenia.
CONCLUSION: Through meta-analysis, we were able to gain insight into previously reported associations between SLC6A4 polymorphism and schizophrenia.

Entities:  

Keywords:  SLC6A4; gene; meta-analysis; polymorphism; schizophrenia

Year:  2018        PMID: 30643413      PMCID: PMC6314053          DOI: 10.2147/NDT.S190563

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Schizophrenia is a complex chronic brain dysfunction that has an elusive pathogenesis and is highly heritable.1 Investigations into twins and adoptees have shown that schizophrenia was caused by both genetic and environmental factors.2,3 Epidemiological genetic studies suggested that genetic factors contributed significantly to the etiology of schizophrenia.4 Pathological mechanisms are based on various neurotransmitter and neurodevelopmental hypotheses, and the hypothesis of a 5-hydroxytryptamine (5-HT) system defect is an important one. The serotoninergic pathway has been implicated, for several reasons, as having a major role in the pathophysiology of schizophrenia. By binding with receptors, 5-HT negatively regulates cAMP-dependent signal transduction and inhibits neuronal activity by opening G-protein–gated inwardly rectifying potassium channels.5 The serotonin transporter (5-HTT) has a crucial function in the regulation of 5-HT reuptake in presynaptic neurons. It has been noted that levels of 5-HTT change in schizophrenic patients.6,7 Significant differences in mRNA levels of the serotonin transporter gene (SLC6A4)8 and serotonin transporter protein levels9 were observed in schizophrenic patients compared with healthy controls. Pharmacological evidence indicated that 5-HTT was a site of action for several drugs with central nervous system effects10,11 and that 5-HTT was involved in the pathogenesis of schizophrenia.12,13 Therefore, the SLC6A4 gene is a candidate gene for the pathogenesis of schizophrenia. The most studied polymorphisms in the SLC6A4 gene are a 44-base pair (bp) insertion–deletion (serotonin-transporter-linked polymorphic region [5-HTTLPR]) in the promoter region, generating major L and S alleles, and a 17-bp variable number of tandem repeats (VNTR) in the second intron (STin2).14 The STin2 consists of 17-bp VNTR elements existing in 9, 10, and 12 repeats (9R, 10R, and 12R), although other rare types, such as seven-repeat units, have also been reported. The single-nucleotide polymorphisms (SNPs), rs1042173 and rs140700, are located in the three prime untranslated region and intron 5 of the SLC6A4 gene, respectively. Associations between the SLC6A4 gene and schizophrenia are controversial.15,16 Ambiguous results from different studies may possibly reflect sample sizes insufficient for obtaining adequate statistical power. A meta-analysis is a useful method for interpreting controversial study results.17,18 Four meta-analyses of the association between the SLC6A4 gene and schizophrenia have been conducted;19–22 however, the results are still controversial. In addition, a meta-analysis of the association between schizophrenia and rs1042173 and rs140700 does not exist. Thus, we intended to perform an updated meta-analysis to better analyze the association of SLC6A4 with schizophrenia.

Materials and methods

Literature searches

To identify studies eligible for inclusion in this meta-analysis, English (PubMed and SchizophreniaGene [SzGene]) and Chinese language (China National Knowledge Infrastructure, Wanfang, and Weipu) databases were searched using the following keywords: “serotonin transporter,” “SERTPR,” “SERT-in2,” “5-HTTLPR,” “STin2 VNTR,” “SLC6A4,” and “schizophrenia.” References of the searched articles were also reviewed to uncover more data.

Inclusion and exclusion criteria

Studies included in the meta-analysis met the following criteria: 1) case–control design; 2) involved patients with schizophrenia; 3) presented relevant data for case and control groups (eg, allele/genotype frequencies, sample size, ethnicity, schizophrenia diagnostic criteria, and control group source); 4) removed duplicate sample data; and 5) published before September 2018. If the article did not contain detailed data, we e-mailed the authors for further information. Studies were excluded for the following reasons: 1) family-based studies; 2) no control group; 3) no usable genotype frequency data (attempts were made to contact authors via e-mail for such data); and 4) duplicate reported sample data.

Statistical analyses

The meta-analysis was conducted using Stata Version 10.0 (Stata Corp., College Station, TX, USA). A P-value of Hardy–Weinberg equilibrium (PHWE) was calculated for control groups. Associations between SLC6A4 and the risk of schizophrenia were detected under the random model.23,24 A suitable genetic model was selected according to the previous articles.25 ORs and 95% CIs were calculated in the pooled and subgroup analyses. The heterogeneity of studies was determined by using Cochran’s chi-squared Q-statistic test.26 The degree of heterogeneity was expressed as I2,which was divided into low (I2<25%), medium (I2~50%), and high (I2>75%) heterogeneity.27,28 Publication bias was calculated by using Egger’s test and was visualized in a funnel plot, in which the SE of the log OR of each study was plotted against its log OR. Sensitivity analysis, by removing one single study in turn, was conducted to test the impact of each study on pooled results. P-values of association, heterogeneity, and publication bias tests were represented by P, P, and P, respectively. In this study, P<0.05 was regarded as statistically significant in all statistical tests.29 Statistical power was calculated by a PS program (Adobe Systems Incorporated, San Jose, CA, USA).25

Results

Description of studies

A total of 380 English and 16 Chinese published research articles were searched, and 46 articles were analyzed in this study after exclusion according to a PRISMA flow program (Figure 1).30 Detailed data on five articles could not be obtained after sending e-mails to the authors;31–35 therefore, they were removed in the present meta-analysis. Table 1 describes the baseline characteristics of 46 studies that were included in this meta-analysis. The studies included 35 articles about 5-HTTLPR,16,36–68 17 studies about Stin2,16,37,39–41,44,47,53,59,65,69–75 four articles about rs1042173,40,47,76,77 and four articles about rs140700.71,76,78,79
Figure 1

Study selection process in this meta-analysis.

Abbreviations: CNKI, China National Knowledge Infrastructure; 5-HTTLPR, serotonin-transporter-linked polymorphic region; STin2 VNTR, second intron variable number of tandem repeats.

Table 1

Characteristics of the qualified studies in this meta-analysis

AuthorsYearCountryEthnicityControls sourceMean age of the control groupCases, nControls, nDiagnostic criteriaGender index (case)Gender index (control)

Li and Li652013People’s Republic of ChinaHanPopulation-based27.7±8.0526528DSM-IV1.0001.000
Frtdtrique et al691997FranceCaucasiansPopulation-based105114DSM-III-R0.4380.932
Pae et al362005KoreaKoreaHospital-based111172DSM-IV1.0900.000
Saiz et al372007SpainCaucasiansPopulation-based40.6±11.3227420DSM-IV0.6670.961
Naylor et al381998AustraliaCaucasiansPopulation-based5862DSM-III-R
Liu et al701999People’s Republic of ChinaHanPopulation-based42.0±10.0260362DSM-III-R0.7090.813
Ikeda et al392006JapanJapanesePopulation-based33.6±12.9287288DSM-IV0.9390.92
Lin et al712009People’s Republic of ChinaHanPopulation-based37.0±8.16329288DSM-IV0.6210.811
Vijayan et al402009IndianIndianPopulation-based31.7±6.92243243DSM-IV
Lee et al412009KoreaKoreaPopulation-based141115DSM-IV
Pae et al422003KoreaKoreaHospital-based30.3±9.4111208DSM-IV1.0960.818
Gu et al432013People’s Republic of ChinaHanPopulation-based22.4±6.6404385ICD-100.5150.629
Kaiser et al162001GermanyCaucasiansPopulation-based30.1±7.6684587DSM-IV0.8870.289
Tsai et al722002People’s Republic of ChinaHanHospital-based42.8±9.2114127DSM-III-R1.4261.822
Herken et al442003TurkeyCaucasiansPopulation-based14368DSM-IV1.860
Serretti et al452002RaffaeleCaucasiansHospital-based46.0±15.5261457DSM-IV1.041
Tsai et al672000People’s Republic of ChinaHanPopulation-based49.6±0.890104DSM-IV0.5252.596
Han et al462004KoreaKoreanHospital-based168158DSM-IV
Zaboli et al472008EuropeanCaucasiansPopulation-based41.0±11.2155246DSM-III-R0.6670.629
Golimbet et al482017RussianRussianPopulation-based34.3±18.11,2851,061ICD-101.6332.333
Herken et al732002TurkishTurkishPopulation-based128135DSM-IV
Peitl et al492017CroatiaCroatiaPopulation-based37.6±11.5300291DSM-IV0.3760.865
Carlstrom et al762012ScandinaviaCaucasiansPopulation-based8371,473DSM-IV
Terzic et al502015LjubljanaSlovenianPopulation-based13894DSM-IV
Lu et al682012the Netherland and GermanyCaucasiansPopulation-based2,0301,288DSM-IV
Golimbet et al512010RussianRussianPopulation-based55.6±20.55862ICD-100.2770.824
Golimbet et al522003RussianRussianHospital-based31.6±13.5110124ICD-100.7461.696
Stober et al531998GermanCaucasianspopulation-based29.9±10.0180223ICD-100.6220.701
Collier et al741996EuropeanCaucasiansPopulation-based129187DSM-III-R
Kotler et al541999Population-based28.0±15.082821ICD-100.5861.61
Rao et al551998The USACaucasiansPopulation-based30.0±10.080127DSM-IV0.6671.953
Rao et al551998The USAAfrican AmericanPopulation-based30.0±8.04737DSM-IV0.7411.313
Pakhomova et al562011RussianRussianPopulation-based18.9±6.765111ICD-100.4440.609
Mendes de Oliveira et al571998EuropeanCaucasiansHospital-based3989DSM-IV
Bayle et al582003FrenchCaucasiansHospital-based35.0±10.0185159DSM-IV0.4340.529
Mata et al592004SpainCaucasiansPopulation-based26.9±5.5187278DSM-IV0.6800.887
Sanjuan et al602006SpainCaucasiansPopulation-based158138DSM-IV0.500
Pal et al792009CroatianCaucasiansPopulation-based50.3±7.5104131ICD-100.705
Chong et al612000East AsiaPopulation-based338103DSM-IV0.565
Pae et al622006KoreansKoreansHospital-based152152DSM-IV
Young et al632006The USACaucasiansPopulation-based1215DSM-IV
Jing et al642016People’s Republic of ChinaHanPopulation-based30.9±6.7624683DSM-IV0.8300.882
Li et al782013People’s Republic of ChinaHanPopulation-based33.1±11.8189300DSM-IV2.3162.297
Yang et al752001People’s Republic of ChinaHanPopulation-based260362DSM-III-R
Zuo et al662003People’s Republic of ChinaHanHospital-based157185CCMD-II-R0.6220.312
Xuan et al772012People’s Republic of ChinaHanPopulation-based132150DSM-IV1.0001.000

Abbreviations: CCMD-II-R, Chinese Classification of Mental Disorders, Second Edition, Revised; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; ICD-10, International Classification of Diseases-10.

No association between 5-HTTLPR and the risk of schizophrenia

In a random model,80,81 the pooled and subgroup analyses of 8,752 cases and 10,610 controls were performed (Table 2). Table 3 summarizes the results of the pooled analyses and Table 4 depicts the data from the subgroup analyses. No association was found between 5-HTTLPR and the risk of schizophrenia with P=0.054 (OR =1.085, 95% CI =0.999–1.178) with a power of 0.935 in the dominant model.82 No associations were found in the subgroup analyses, except in an Indian group (P=0.014, OR =1.749, 95% CI =1.120–2.731). No significant heterogeneity was observed in the pooled analysis (P=0.294, I2=10.4%).
Table 2

Genotype distribution and allele frequency of 5-HTTLPR

AuthorsYearGenotype distribution
PHWEAllele frequency
Cases, n
Controls, n
Cases, %
Controls, %
LLLSSSLLLSSSLSLS

Pae et al3620054357210491130.1434317969275
Saiz20076410459124203930.566232222451389
Naylor et al3819981130171929140.64652646757
Ikeda et al3920061682189121011750.588114460125451
Vijayan et al402009401237962118610.748203281242240
Lee et al41200975282345670.1516621651179
Pae et al4220034357211581390.1404317980336
Gu et al432013141012897902880.992129679104666
Kaiser et al162001253324107207286940.772830538700474
Herken et al4420033070401724270.0221301505878
Serretti et al4520028912151165217750.800299223547367
Tsai et al671999928531530590.0024613460148
Han et al462004752109854960.9106627070246
Zaboli et al47200856732675126450.532185125276216
Golimbet et al4820174865952044135031450.6771,5671,0031,329793
Peitl et al49201711812458103138500.746360240344238
Terzic20155271154734130.10417510112860
Lu et al6820124076262546909923450.7191,4401,1342,3721,682
Golimbet et al5120102720112228120.56774427252
Golimbet et al5220034246224557220.59413090147101
Stober199858903279112420.834206154270196
Kotler et al5419992438202104461650.0108678866776
Rao et al5519982832204359250.5598872145109
Rao et al55199825184181270.07968264826
Pakhomova2011203784348200.310775313488
Mendes de Oliveira et al571998122163943160.480453312175
Bayle et al5820034899384083360.573195175163155
Mata et al592004411024463124910.100184190250306
Sanjuan et al6020063378474468260.976144172156120
Chong et al612000331301751332580.01919648058148
Pae et al622006546101947960.3225624865239
Young20062556720.9859151911
Jing et al64201651267306662483690.012369879380986
Li et al782013535149241341420.32545333182418
Zuo200315509221491150.0008023491279

Abbreviations: 5-HTTLPR, serotonin-transporter-linked polymorphic region; PHWE, P-value of Hardy–Weinberg equilibrium.

Table 3

Pooled association of SLC6A4 polymorphisms with schizophrenia

LociGenetic modelStudies (n)StatisticalOR95% CIPzI2PhPe

5-HTTLPRAllele contrast35Random0.9340.868–1.0040.06653.60.0000.587
Homozygous codominant35Random1.1420.782–0.9800.02115.60.2060.912
Heterozygous codominant35Random1.0660.980–1.1610.1387.70.3400.165
Dominant35Random1.0850.999–1.1780.05410.40.2940.211
Recessive35Random1.0820.961–1.2180.19557.80.0000.846
STin2 VNTR10R vs others17Random0.8840.725–1.0770.22182.80.0000.951
12R vs others17Random1.1340.931–1.3810.2182.80.0000.936
10R/10R vs others17Random0.9070.624–1.3190.61178.90.0000.401
10R/12R vs others17Random0.7890.646–0.9630.02071.10.0000.748
12R/12R vs others17Random1.9361.238–3.0290.00494.70.0000.474
rs1042173Contrast4Random1.0940.962–1.2450.1722.70.2750.412
Homozygous codominant4Random1.2140.921–1.6000.16926.40.2530.336
Heterozygous codominant4Random1.0110.812–1.2600.92018.00.3010.941
Dominant4Random1.0770.856–1.3540.52826.90.2500.722
Recessive4Random1.1990.994–1.4450.05714.50.3200.155
rs140700Allele contrast4Random1.0520.519–1.7340.86392.90.0000.359
Homozygous codominant4Random0.8090.236–2.7740.73663.70.0410.223
Heterozygous codominant4Random0.9710.500–1.8840.93191.90.0000.685
Dominant4Random1.0030.503–1.9990.99393.20.0000.560
Recessive4Random0.8300.284–2.4220.73353.50.0920.333

Abbreviations: 5-HTTLPR, serotonin-transporter-linked polymorphic region; P, P, and P, P-values of association, heterogeneity, and publication bias tests, respectively; R, repeats; STin2 VNTR, second intron variable number of tandem repeats.

Table 4

Subgroup association of SLC6A4 polymorphisms with schizophrenia

LociSubgroup analysisStudies (n)OR95% CIPzI2Ph

5HTTLPRCaucasians211.0530.974–1.1380.1921.60.437
East Asia121.2040.953–1.5210.1194.10.404
African American10.8340.352–1.9750.6790.00.000
Indians11.7491.120–2.7310.0140.00.000
Population-based261.0890.982–1.2090.13128.30.090
Hospital-based91.0940.897–1.3350.2730.00.939
STin2 VNTR 1010Caucasians90.8830.645–1.2070.43563.70.005
East Asia70.8570.310–2.3740.76775.50.00
Indians10.6390.368–1.1080.1110.000
Population-based160.9300.639–1.3540.70479.80.000
Hospital-based10.1550.008–3.0400.220
1012Caucasians90.9440.832–1.0720.3740.00.706
East Asia70.6170.389–0.9780.04080.80.000
Indians10.6350.441–0.9130.014
Population-based160.7940.646–0.9760.02872.80.000
Hospital-based10.6670.290–1.5360.341
1212Caucasians91.0420.916–1.1860.5310.00.885
East Asia74.4822.312–8.6890.00092.10.000
Indians11.5731.086–2.2800.170
Population-based161.7551.124–2.7420.01394.50.000
Hospital-based110.6895.303–21.5440.000
rs1042173Caucasians21.2991.0791.5650.0060.00.421
East Asia10.8340.5171.3460.458
Indians11.2130.7981.8430.365
rs140700Caucasians21.2530.8271.8960.28742.60.187
East Asia20.7570.2152.6700.66593.50.000

Abbreviations: 5-HTTLPR, serotonin-transporter-linked polymorphic region; P and P, P-values of association and heterogeneity, respectively; STin2 VNTR, second intron variable number of tandem repeats.

Genotypes 10R/12R and 12R/12R of STin2 VNTR may be associated with the risk of schizophrenia

The allele frequencies of 7,284 cases and 8,544 controls were included in the pooled and subgroup analyses, under a random model (Table 5); 10R and 12R are common alleles; therefore, alleles (10R and 12R) and genotypes (10R/10R, 10R/12R, and 12R/12R) were analyzed for an association with the risk of schizophrenia, respectively (Tables 3 and 4). A 10R/12R genotype was a protective factor against schizophrenia (P=0.020, OR =0.789, 95% CI =0.646–0.963), but a 12R/12R genotype was a risk factor for schizophrenia (P=0.004, OR =1.936, 95% CI =1.238–3.029) in the pooled analyses. The two pooled analyses had high powers of 1.000. In the subgroup analyses, 10R/12R was a protective factor against schizophrenia in East Asia (P=0.040, OR =0.617, 95% CI =0.389–0.978), India (P=0.014, OR =0.635, 95% CI =0.441–0.913) and in a population-based analysis (P=0.028, OR =0.794, 95% CI =0.646–0.976). A 12R/12R genotype was a risk factor for schizophrenia in East Asia (P=0.000, OR =4.482, 95% CI =2.312–8.689) and in population-based (P=0.013, OR =1.755, 95% CI =1.124–2.742) and hospital-based (P=0.000, OR =10.689, 95% CI =5.303–21.544) subgroup analyses. The significant heterogeneity was observed in these associated analyses.
Table 5

Genotype distribution and allele frequency of STin2 VNTR

AuthorsYearGenotype distribution
Allele frequency
Case
Control
Case
Control
1012Others1012Others101010121212Others101010121212Others

Frtdtrique199784120679143624363961841505
Saiz2007171281230553054286972641771745
Liu et al70199922498058665121824005483081
Ikeda et al39200651523046530014923703402450
Lin et al712009554250107457064319109891840
Vijayan et al402009137343018929702489127036117900
Lee et al4120093624602320704281090317950
Kaiser et al1620014938354048566821952912593910825919921
Tsai et al72200210218022232001010403161080
Herken et al442003822040315901258730815220
Zaboli et al47200812218401763020306261029118920
Herken et al732002721840711981954650757701
Stober19981412172204254829836625496758
Collier et al741996941622169202319565224285573
Mata et al59200410322101782880157374037104920
Li et al78201333345041818201493550142134240
Yang200122498058665121824005483081

Abbreviation: STin2 VNTR, second intron variable number of tandem repeats.

Genotype GG of rs1042173 may be a risk factor for schizophrenia in Caucasians

In a recessive and a random model, no association was detected among 1,351 cases and 2,101 controls (P=0.057, OR =1.199, 95% CI =0.994–1.445; Table 6). Tables 3 and 4 shows the results. In Caucasians, a GG genotype may be a risk factor for schizophrenia (P=0.006, OR =1.299, 95% CI =1.079–1.565), with a power of 0.893. No significant heterogeneity was observed in the pooled or subgroup analyses.
Table 6

Genotype distribution and allele frequency of rs1042173

AuthorsYearGenotype distribution
PHWEAllele frequency
Cases, n
Controls, n
Cases, %
Controls, %
GGGTTTGGGTTTGTGT

Vijayan et al402009631195055112670.538245219222246
Zaboli et al47200839783858129590.444156154245247
Carlstrom20122074022232917704100.0398168481,3521,590
Xuan et al772012774312944880.5681976723664

Abbreviation: PHWE, P-value of Hardy–Weinberg equilibrium.

No association between rs140700 and the risk of schizophrenia

Under a random model, the allele frequencies of 1,770 cases and 2,386 controls were included in the pooled and subgroup analyses (Table 7). In a dominant model, no association was detected between rs140700 and the risk of schizophrenia in the pooled and subgroup analyses (Tables 3 and 4). Significant heterogeneity was observed in the pooled (P=0.000, I2=93.2%) and East Asia subgroup (P=0.000, I2=93.5%) analyses.
Table 7

Genotype distribution and allele frequency of rs140700

AuthorsYearGenotype distribution
PHWEAllele frequency
Cases, n
Controls, n
Cases, %
Controls, %
GGGAAAGGGAAAGAGA

Li et al78201336912730259212570.173865187730326
Lin et al7120092773022441810.2955843450620
Carlstrom201268914021,233221100.9771,5181442,687241
Pal et al792009801951121810.7691792924220

Abbreviation: PHWE, P-value of Hardy–Weinberg equilibrium.

Sensitivity analysis

We conducted sensitivity analyses by omitting each study individually; the pooled ORs did not change significantly. Thus, the results were considered stable and reasonable.

Publication bias

Any publication bias was made visible by funnel plots, in which the SE of the log OR of each study was plotted against its log OR. No evidence of publication bias was found in the pooled analyses (Figures 2–7).
Figure 2

Funnel plot analysis on the detection of publication bias in the association between 5-HTTLPR (SS + LS vs LL) and schizophrenia.

Abbreviation: 5-HTTLPR, serotonin-transporter-linked polymorphic region.

Figure 3

Funnel plot analysis on the detection of publication bias in the association between STin2 VNTR (10R/10R vs others) and schizophrenia.

Abbreviation: STin2 VNTR, second intron variable number of tandem repeats.

Figure 4

Funnel plot analysis on the detection of publication bias in the association between STin2 VNTR (10R/12R vs others) and schizophrenia.

Abbreviation: STin2 VNTR, second intron variable number of tandem repeats.

Figure 5

Funnel plot analysis on the detection of publication bias in the association between STin2 VNTR (12R/12R vs others) and schizophrenia.

Abbreviation: STin2 VNTR, second intron variable number of tandem repeats.

Figure 6

Funnel plot analysis on the detection of publication bias in the association between rs1042173 (GG vs GT + TT) and schizophrenia.

Figure 7

Funnel plot analysis on the detection of publication bias in the association between rs140700 (AA + AG vs GG) and schizophrenia.

Discussion

We found no association between 5-HTTLPR and the risk of schizophrenia, except in Indians. The scale for Indians was small and was found in only one article; therefore, the association may be a false-positive. A negative association between 5-HTTLPR and the risk of schizophrenia was consistent with the results of the previous meta-analyses,19,21 but inconsistent with the results of Allen et al.22 Differences may exist in results found because Allen et al only analyzed articles on the SzGene in their meta-analysis. An association between suicidal behavior and 5-HTTLPR was not detected in a recent meta-analysis,83 which conflicts with previous evidence suggesting an association between 5-HTTLPR and violent suicidal behavior. The L allele of the 5-HTTLPR was reported as improving transcription of the SLC6A4 gene.84 A meta-analysis noted an association between the S allele of 5-HTTLPR and the risk of bipolar disorder.85 Psychiatric disorders share genetic variants.21 A haplotype, including 5-HTTLPR and rs16965628 markers, is thought to be associated with an obsessive–compulsive disorder.86 Therefore, 5-HTTLPR may link with other SNPs to influence the serotoninergic pathway. STin2 VNTR was associated with the risk of schizophrenia, but a significant difference was not detected in the allele analysis, inconsistent with other meta-analyses.19,20 Gatt et al reviewed the relevant meta-analysis between STin2 VNTR and schizophrenia and found that the 12R genotype was associated with schizophrenia as a protective factor, while 9R and 10R genotypes were not associated with schizophrenia.21 Our results showed that the 10R/12R genotype was a protective factor for schizophrenia, while the 12R/12R genotype was a risk factor for schizophrenia, in the pooled and several subgroup analyses. Genotypes with 12R may significantly increase relative 5-HTT gene expression,87 leading to increasing vulnerability to schizophrenia. STin2.12R has a superior enhancer-like property within the developing rostral hindbrain, which may lead to aberrant serotonergic neuronal development.40,88 In addition, STin2 acts as a transcriptional regulator in an allele-dependent manner in the developing mouse brain.89 Haplotype analysis demonstrated that two STin2-containing haplotypes were associated with the risk of schizophrenia, but no association was found in the single locus.71 No association was detected in Caucasians and Indians, which may be the result of different genetic backgrounds. Significant heterogeneity was assessed in the pooled analysis, and heterogeneity was found in all subgroups, except Caucasians. This was the first meta-analysis of the association between the risk of schizophrenia and rs1042173 and rs140700. Gatt et al comprehensively reviewed a meta-analysis of the association between SLC6A4 (5-HTTLPR and STin2 VNTR) and schizophrenia.21 To some extent, it would seem that our meta-analysis is superfluous. However, it was an updated analysis, assessing the association of the SLC6A4 gene with schizophrenia using high statistical powers. Our study also included seven studies published after 2013 and three studies in Chinese. Moreover, four variations (5-HTTLPR, STin2 VNTR, rs1042173, and rs140700) were analyzed in our meta-analysis. Genome-wide association studies (GWASs) can discover novel and unexpected candidate loci in an unbiased manner. Previous GWAS analyses found that the SLC6A4 gene was not associated with schizophrenia.90–93 A comparison of 12 single-disorder GWAS meta-analyses suggested no overlap in significant genetic variants identified from the different studies.21 However, structural magnetic resonance imaging scans suggested that SLC6A4 was related to deficits of brain structural networks in schizophrenia.94 Our results are inconsistent with those of the previous meta-analysis. Several reasons for this may exist: First, many recently published studies were included in our analysis; therefore, the scale of samples used was larger than those used before. Second, the articles from both English and Chinese language databases were included. Third, geographical environment, culture, lifestyle, and genetic background and diseases may affect genetic polymorphisms.95,96 Significant heterogeneity was found in overall and subgroup analyses, especially for STin2 VNTR and rs140700. Although we performed subgroup analyses according to ethnicity to investigate potential sources of heterogeneity, this did not completely account for the heterogeneity. These results suggest that other aspects may partially contribute to heterogeneity, such as distinct genetic backgrounds and the different habits and customs of the people sampled.97 Overall, however, the results described herein should be interpreted with caution. First, the small sample size for rs1042173 and rs140700 should be borne in mind. Several associations only appeared in the subgroup analyses, for which only one or two articles were used. Therefore, these samples may not be representative and comprehensive. In addition, it was hard to conduct subgroup analyses for some SNPs because of so few articles. Second, deviations in the PHWE and significant heterogeneity were observed in this study because of sample bias. Third, family-based studies, which were more robust than case–control designs, were not included in this analysis.98–101 Fourth, interactions between multiple genes and SNPs may affect the risk of schizophrenia,21 meaning that genetic interactional and functional studies are needed.

Conclusion

Our meta-analysis showed a lack of association between 5-HTTLPR and the risk of schizophrenia, except in an Indian subgroup analysis. The 10R/12R genotype was a protective factor against schizophrenia, while the12R/12R genotype was a risk factor for schizophrenia in the pooled analyses. In Caucasians, the GG genotype of rs1042173 may be a risk factor for schizophrenia. No association was found between rs140700 and the risk of schizophrenia. Increased genetic interactional and functional studies are warranted to explore the association between polymorphisms of the SLC6A4 gene and schizophrenia risk.
  96 in total

1.  An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells.

Authors:  C E Fiskerstrand; E A Lovejoy; J P Quinn
Journal:  FEBS Lett       Date:  1999-09-17       Impact factor: 4.124

Review 2.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics.

Authors:  A G Cardno; I I Gottesman
Journal:  Am J Med Genet       Date:  2000

3.  A rare short allele of the serotonin transporter promoter region (5-HTTLPR) found in an aggressive schizophrenic patient of Jewish Libyan origin.

Authors:  A Frisch; B Finkel; E Michaelovsky; M Sigal; N Laor; R Weizman
Journal:  Psychiatr Genet       Date:  2000-12       Impact factor: 2.458

4.  Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia.

Authors:  R Kaiser; P B Tremblay; J Schmider; M Henneken; M Dettling; B Müller-Oerlinghausen; R Uebelhack; I Roots; J Brockmöller
Journal:  Mol Psychiatry       Date:  2001-03       Impact factor: 15.992

5.  Attempted suicide and polymorphism of the serotonin transporter gene in Chinese patients with schizophrenia.

Authors:  S A Chong; W L Lee; C H Tan; A H Tay; A O Chan; E C Tan
Journal:  Psychiatry Res       Date:  2000-12-27       Impact factor: 3.222

6.  Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity.

Authors:  M Kotler; P Barak; H Cohen; I E Averbuch; A Grinshpoon; I Gritsenko; L Nemanov; R P Ebstein
Journal:  Am J Med Genet       Date:  1999-12-15

7.  Family-based association studies of monoaminergic gene polymorphisms among North Indians with schizophrenia.

Authors:  P Semwal; S Prasad; T Bhatia; S N Deshpande; J Wood; V L Nimgaonkar; B K Thelma
Journal:  Mol Psychiatry       Date:  2001-03       Impact factor: 15.992

8.  [Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies].

Authors:  O S Brusov; M I Faktor; G P Zlobina; P V Bologov; V G Kaleda; I V Oleĭchik; A N Korenev; A N Piatnitskiĭ; A M Dupin; A B Katasonov; M A Morozova; A G Beniashvili; R Kh Lozier; E V Pavlova; O L Segal; Iu S Massino; A D Dmitriev
Journal:  Vestn Ross Akad Med Nauk       Date:  2001

9.  Tentative association of the serotonin transporter with schizophrenia and unipolar depression but not with bipolar disorder in Han Chinese.

Authors:  W Liu; N Gu; G Feng; S Li; S Bai; J Zhang; T Shen; H Xue; G Breen; D St Clair; L He
Journal:  Pharmacogenetics       Date:  1999-08

10.  Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response.

Authors:  S J Tsai; C J Hong; Y W Yu; C H Lin; H L Song; H C Lai; K H Yang
Journal:  Schizophr Res       Date:  2000-09-01       Impact factor: 4.939

View more
  6 in total

1.  The effects of 5-HTTLPR/rs25531 serotonin transporter gene polymorphisms on antisocial personality disorder among criminals in a sample of the Turkish population.

Authors:  Irmak Sah; Emel Hulya Yukseloglu; Nese Kocabasoglu; Burcu Bayoglu; Emre Cirakoglu; Mujgan Cengiz
Journal:  Mol Biol Rep       Date:  2021-01-15       Impact factor: 2.316

Review 2.  Revisiting tandem repeats in psychiatric disorders from perspectives of genetics, physiology, and brain evolution.

Authors:  Xiao Xiao; Chu-Yi Zhang; Zhuohua Zhang; Zhonghua Hu; Ming Li; Tao Li
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

3.  Receptor-Mediated AKT/PI3K Signalling and Behavioural Alterations in Zebrafish Larvae Reveal Association between Schizophrenia and Opioid Use Disorder.

Authors:  Siroshini K Thiagarajan; Siew Ying Mok; Satoshi Ogawa; Ishwar S Parhar; Pek Yee Tang
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

4.  The presence of polymorphisms in genes controlling neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia.

Authors:  Gennady M Zharinov; Sergei E Khalchitsky; Alexandre Loktionov; Marina V Sogoyan; Yulia V Khutoryanskaya; Natalia Yu Neklasova; Oleg A Bogomolov; Ilya V Smirnov; Marina P Samoilovich; Vladimir N Skakun; Sergei V Vissarionov; Vladimir N Anisimov
Journal:  Oncotarget       Date:  2021-03-30

5.  Serotonin transporter functional polymorphisms potentially increase risk of schizophrenia separately and as a haplotype.

Authors:  Rana Ghamari; Fatemeh Yazarlou; Zahra Khosravizadeh; Atefeh Moradkhani; Elaheh Abdollahi; Fatemeh Alizadeh
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

6.  Association between RGS4 gene polymorphisms and schizophrenia: A protocol for systematic review and meta-analysis.

Authors:  Feng-Ling Xu; Jun Yao; Bao-Jie Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.